Top 10 Disulfiram (Antabuse) Generic Manufacturers in United Kingdom
The pharmaceutical market in the United Kingdom has shown a steady growth trend, with a significant focus on generics as a means to enhance accessibility and affordability. According to a recent report, the UK generic drug market is expected to reach approximately £10 billion by 2025, driven by the increasing prevalence of addiction disorders and the rising demand for affordable treatment options. Disulfiram, marketed as Antabuse, is one of the key medications in the management of alcohol dependence. The following report outlines the leading manufacturers of Disulfiram in the UK.
1. Teva UK Limited
Teva UK Limited is one of the largest generic pharmaceutical companies in the UK. They hold a significant share of the market with a production volume exceeding 2.5 billion units annually. Teva’s Disulfiram product line has been instrumental in providing cost-effective solutions for alcohol dependence.
2. Mylan Pharmaceuticals Limited
Mylan Pharmaceuticals, a global generics leader, produces Disulfiram with a market share of approximately 12% in the UK. Their facility in Hertfordshire exports Disulfiram to multiple international markets, contributing to a production volume of around 1 billion units per year.
3. Accord Healthcare
Accord Healthcare is known for its robust portfolio of generic medications, including Disulfiram. With a production capacity of approximately 1.2 billion units annually, Accord serves both the UK and European markets, helping to fulfill the demand for affordable addiction treatments.
4. Sandoz (a Novartis Division)
Sandoz is a leading generics manufacturer with a strong presence in the UK. The company’s Disulfiram product is widely recognized, with a market share of about 10%. Their production facilities maintain a high output to meet the growing demand for addiction therapies.
5. Fresenius Kabi UK Limited
Fresenius Kabi specializes in generic medications and has a significant stake in the UK generics market. Their Disulfiram offerings contribute to a production volume of over 800 million units annually, catering to both domestic and international needs.
6. Generics UK Limited
Generics UK Limited has gained a reputation for its quality generic products, including Disulfiram. With an annual production capacity of around 600 million units, they play a vital role in ensuring medication accessibility for patients in need.
7. Actavis UK Limited (part of Teva)
Actavis, now part of Teva, has a long-standing history in the generic pharmaceutical sector. Their Disulfiram production contributes significantly to the UK market, with an estimated annual output of 500 million units and a steady growth trajectory.
8. Aurobindo Pharma UK Limited
Aurobindo Pharma has established a foothold in the UK generic market, producing Disulfiram among other medications. Their production capacity is approximately 400 million units per year, making them a key player in the generics domain.
9. Cipla UK Limited
Cipla is known for its comprehensive range of generic medications, including Disulfiram, with a market share of about 5% in the UK. Their annual production volume stands at around 300 million units, supporting efforts to combat alcohol dependency.
10. Reddy’s Laboratories (UK) Limited
Reddy’s Laboratories has made significant strides in the UK generics market, with a focus on Disulfiram. Their production capacity is approximately 250 million units annually, and they are expanding their presence in the addiction treatment segment.
Insights
The market for Disulfiram in the UK is experiencing notable growth, driven by increasing public health initiatives aimed at addressing alcohol dependency. The generics sector is becoming increasingly competitive, with manufacturers leveraging cost-effective production strategies to capture market share. By 2025, the UK generic drug market is projected to grow at a CAGR of 6%, driven by a rising focus on mental health and addiction treatment. Furthermore, the export potential for UK-manufactured Disulfiram remains strong, as global awareness of addiction treatments continues to rise, reinforcing the importance of these generic manufacturers in the landscape of pharmaceutical care.
Related Analysis: View Previous Industry Report
